Medford, MA, May 20, 2026 — PolyBio Research Foundation today announced the formal launch of its Commercialization Advisory Network, a new initiative designed to accelerate the translation of Long COVID and related chronic disease discoveries into clinical diagnostics and targeted treatments. While initially focused on Long COVID through PolyBio’s Long COVID Cure Initiative (LCCI), the Network will also help guide translational efforts in related infection-associated chronic illnesses including chronic Lyme disease, Alzheimer’s, and aspects of human aging increasingly linked to chronic infection and immune dysfunction.
The Network held its inaugural meeting on Friday, May 15 at the Harvard Innovation Labs in Boston, bringing together leaders across diagnostics, biotechnology, healthcare investment, reimbursement strategy, and translational medicine.
The Network will help guide the commercialization and deployment of next-generation diagnostic platforms capable of identifying key biological drivers of Long COVID, including persistent viral reservoirs, pathogen reactivation, and immune dysfunction.
“The bottleneck in Long COVID is no longer simply discovery,” said Caroline Rossiter, PolyBio’s Director of Operations and Innovation. “Academic researchers are increasingly identifying clear biological abnormalities in patients. The challenge now is to help them translate those findings into validated diagnostics, targeted clinical trials, and treatments that can actually reach patients. The Commercialization Advisory Network was built specifically to help solve that problem.”
A central focus of the initiative is VIPER, PolyBio’s large-scale Long COVID diagnostics validation program. Modeled in part after successful HIV assay validation efforts, VIPER is designed to rigorously compare and validate diagnostic technologies across laboratories and patient cohorts, with the goal of identifying the assays best positioned for clinical deployment and use in mechanistic clinical trials.
Members of the Network bring expertise spanning the full translation process: diagnostic product development, liquid biopsy technologies, reimbursement and insurance strategy, venture creation, companion diagnostics, and biotechnology commercialization. The group includes leaders from StudioDx, AnywhereDx, Exosome Diagnostics, Santé Ventures, Invivyd, Enanta Pharmaceuticals, American Cancer Society BrightEdge, and The Michael J. Fox Foundation for Parkinson’s Research.
The first meeting focused on strategies to accelerate the validation, commercialization, and clinical adoption of Long COVID diagnostics being advanced through the Long COVID Cure Initiative. Discussions included regulatory strategy, payer adoption, clinical trial integration, commercialization pathways for academic technologies, and approaches to building companion diagnostics that can help match patients with targeted therapies.
More information about the Long COVID Cure Initiative is available here.
About PolyBio Research Foundation
PolyBio Research Foundation is a 501(c)(3) organization advancing research on how viral, bacterial, and parasitic infections drive chronic disease and aging. We build collaborative projects that identify, diagnose, and treat root causes of infection-associated chronic illness.